Last reviewed · How we verify
Dasatinib Tablets
Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and multiple other kinases involved in cancer cell proliferation and survival.
Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and multiple other kinases involved in cancer cell proliferation and survival. Used for Chronic myeloid leukemia (CML), chronic phase, accelerated phase, and blast crisis, Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
At a glance
| Generic name | Dasatinib Tablets |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | BCR-ABL tyrosine kinase inhibitor |
| Target | BCR-ABL, SRC family kinases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Dasatinib inhibits the BCR-ABL fusion protein that drives chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It also inhibits SRC family kinases and other tyrosine kinases, providing a broader spectrum of activity than earlier-generation ABL inhibitors. This multi-targeted approach can overcome some resistance mechanisms and provide activity against certain BCR-ABL mutations.
Approved indications
- Chronic myeloid leukemia (CML), chronic phase, accelerated phase, and blast crisis
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Common side effects
- Pleural effusion
- Diarrhea
- Headache
- Fatigue
- Nausea
- Rash
- Fluid retention
- Myelosuppression
Key clinical trials
- Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects (PHASE2, PHASE3)
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (PHASE3)
- Dasatinib for HIV-1 Reservoir Reduction (PHASE1)
- Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease (PHASE1, PHASE2)
- ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- Senolytics to Improve Osteoporosis Therapy (PHASE2)
- Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment (PHASE2)
- A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dasatinib Tablets CI brief — competitive landscape report
- Dasatinib Tablets updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI